COMMUNIQUÉS West-GlobeNewswire

Imprivata Enterprise Access Management Wins 2026 Best in KLAS Award for Access Management
04/02/2026
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Imprivata , a leading provider of access management solutions for healthcare and other mission-critical industries, today announced that Imprivata Enterprise Access [...]
Normunity to Participate in the TD Cowen 46ᵗʰ Annual Health Care Conference
04/02/2026
BOSTON and NEW HAVEN, Conn., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Normunity , a clinical stage biotechnology company pioneering precision biologics, today announced that management will participate in the TD Cowen 46 th [...]
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
04/02/2026
NAARDEN, The Netherlands and MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
R1 Awarded ‘Best in KLAS’ Across Multiple RCM Categories for 2026
04/02/2026
Providers Recognize R1 for Unwavering Commitment to Launching Innovative Technology CHICAGO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), the leader in healthcare revenue management, has been named a [...]
The Noom Engagement Report: New Data Shows that the GLP-1 Patients Who Use Noom the Most Also Lose the Most Weight and Stay On Medication Program Longest
04/02/2026
Most-engaged members lost 25.2% more weight at week 40 and persisted 2.2x longer on medication program than least-engaged members using the Noom app, demonstrating the benefits of combining GLP-1 medication with Noom’s [...]
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™
04/02/2026
Real-world and clinical trial data underscore long-term safety and effectiveness in pediatric and adult NPC patients CELEBRATION, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra [...]
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
04/02/2026
Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population Company to launch controlled study in second-line KRAS-mutant MSS mCRC with [...]
NewGen and Evident Capital Successfully Activate Commitment Campaign for Inaugural Tokenized Real Estate Bond, Delivering on Cross-Border Real World Asset Financing Strategy
04/02/2026
Rapid progress from announcement of successful launch in under two weeks signals NewGen’s expertise and commitment Launch represents fulfilment of NewGen’s goals to spearhead Real World Asset tokenization, puts Company [...]
Bionano Announces Publication from Sanford Burnham Prebys Medical Discovery Institute Describing use of OGM to Detect Genomic Alterations Introduced by Gene Editing Technologies
04/02/2026
SAN DIEGO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced a peer-reviewed study published in Molecular Therapy - Methods & Clinical Development , describing the application of [...]
Cannara annonce un placement privé stratégique sans intermédiaire de 6,3 millions $ CA au prix de 2,10 $ CA par action ordinaire
04/02/2026
MONTRÉAL, 04 févr. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », « la Société », « nous » ou « notre ») ( TSXV : LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), producteur verticalement intégré de cannabis de [...]
Control the Stack, Control the Future: The New Era of Supply-Chain Power
04/02/2026
DENVER, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Innovation still rules, but ownership of the entire supply-chain pipeline is becoming the next biggest strategic advantage in today’s markets. From raw inputs to final delivery [...]
Cannara Announces Strategic C$6.3 Million Non-Brokered Private Placement Priced at C$2.10 per Common Share
04/02/2026
MONTREAL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
CytomX Therapeutics to Present at Upcoming February Conferences
04/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will [...]
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
04/02/2026
MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
04/02/2026
PRINCETON, N.J., Feb. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
04/02/2026
February 4, 2026 Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models Cardiff, UK – [...]
Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
MINNEAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the [...]
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
04/02/2026
Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 mg nusinersen The high-dose regimen of [...]
Levicept Announces the Appointment of James Sandy as Chief Development Officer
04/02/2026
Leadership Team Strengthened to Support Clinical Development of LEVI-04 for Osteoarthritis SANDWICH, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of [...]

Pages